Adamas Pharmaceuticals, Inc. company logo

# 1st Gen Model Adamas Pharmaceuticals, Inc. Pharmaceutical preparations

Subscribe >> Deal exit on
June 5, 2017
Deal entry on
June 5, 2017
6.41%Expected margin
64.29% successful of 42 deals
$19.26 Last close price
at 20-oct-2017

ADMS

Model's trade recommendations 0.00% Return for period

-2.70% Annual return

$0.43B Market Cap

β 0.78  

ADMS

Model (following trade recommendations)

ADMS

Underlying stock

S&P 500

Index
Return for period 0.00%
-9.32%
1.78%
52wk return 26.17%
32.01%
16.82%
52wk Range
12.24—23.81
2000.54—2399.63
Sortino ratio 0.09
Sharpe ratio 0.07
Norm. RMSE 0.63%
Downside risk 25.76%
Volatility 30.53%
  • STRONG BUY Analysts consensus recommendation

Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson's disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company's portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Adamas Pharmaceuticals, Inc. (ADMS) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 2, 2015.

Market data for ADMS model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 16M
P/E NaN
Shares Outstanding 23M
% Held by Insiders 29.00%
% Held by Institutions 71.95%
EPS (last reported FY) $-2.77
EPS (last reported Q) $-0.93
EPS, estimated (last reported Q) $-0.85
Total revenues $0 B
Net income $-0 B